

Small Molecules

A 83-01

Activin/NODAL/TGF- β pathway inhibitor; Inhibits ALK5, ALK4, and ALK7

Catalog # 72022
72024

5 mg
10 mg



Scientists Helping Scientists™ | WWW.STEMCELL.COM

TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713


INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM

FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

A 83-01 is a potent inhibitor of activin receptor-like kinase (ALK) including ALK5 (type I transforming growth factor- β receptor), ALK4 (type IB activin receptor), and ALK7 (type I NODAL receptor) with IC_{50} = 12, 45, and 7.5 nM, respectively (Tojo et al.).

Molecular Name:	A 83-01
Alternative Names:	Not applicable
CAS Number:	909910-43-6
Chemical Formula:	C ₂₅ H ₁₉ N ₅ S
Molecular Weight:	421.5 g/mol
Purity:	≥ 95%
Chemical Name:	3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide
Structure:	



Properties

Physical Appearance:	A crystalline solid
Storage:	Product stable at -20°C as supplied. Protect from prolonged exposure to light. For long-term storage store with a desiccant. Stable as supplied for 12 months from date of receipt.
Solubility:	· DMSO \leq 30 mM · Absolute ethanol \leq 0.5 mM For example, to prepare a 10 mM stock solution in DMSO, resuspend 1 mg in 237 μ L of DMSO.

Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported, however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application.

Compound has low solubility in aqueous media. For use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use. Avoid final DMSO concentration above 0.1% due to potential cell toxicity.

Published Applications

MAINTENANCE AND SELF-RENEWAL

- Facilitates the conversion of epiblast stem cells to the naïve pluripotent state (Zhou et al.; Li et al.).

REPROGRAMMING

- In combination with PD0325901 (Catalog #72182), enables OCT4-mediated reprogramming (Zhu et al.).

DIFFERENTIATION

- Inhibits mesoderm and endoderm specification (Zhang et al.).
- Disrupts epithelial to mesenchymal transition through inhibition of the SMAD signaling pathway (Tojo et al.).

References

- Li W et al. (2009) Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. *Cell Stem Cell* 4(1): 16–9.
- Tojo M et al. (2005) The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. *Cancer Sci* 96(11): 791–800.
- Zhang M et al. (2016) Pharmacological reprogramming of fibroblasts into neural stem cells by signaling-directed transcriptional activation. *Cell Stem Cell* 18(5): 653–67.
- Zhou H et al. (2010) Conversion of mouse epiblast stem cells to an earlier pluripotency state by small molecules. *J Biol Chem* 285(39): 29676–80.
- Zhu S et al. (2010) Reprogramming of human primary somatic cells by OCT4 and chemical compounds. *Cell Stem Cell* 7(6): 651–5.

Related Small Molecules

For a complete list of small molecules available from STEMCELL Technologies, visit www.stemcell.com/smallmolecules or contact us at techsupport@stemcell.com.

This product is hazardous. Please refer to the Safety Data Sheet (SDS).

STEMCELL TECHNOLOGIES INC.'S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2017 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, and Scientists Helping Scientists are trademarks of STEMCELL Technologies Canada Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.